Inotuzumab Concerns and CAR T-Transplant Sequencing

Dr. Muffly addresses common concerns from referring physicians regarding inotuzumab use before transplant due to veno-occlusive disease (VOD) risk, and questions about CAR T-cell therapy expense when transplant remains planned. Dr. Park acknowledges these valid concerns while providing practical management strategies for both scenarios.

Regarding inotuzumab and VOD risk, Dr. Park recommends limiting exposure to maximum two cycles, as treatment efficacy becomes apparent after one cycle. He employs strategies including combination approaches with reduced-intensity chemotherapy plus lower-dose inotuzumab for chemosensitive patients, minimizing inotuzumab exposure while maintaining efficacy. When transplant colleagues request extended intervals between inotuzumab and conditioning, Dr. Park uses blinatumomab as bridging therapy to maintain remission while extending the time gap, though optimal timing lacks definitive data-driven guidance.

For CAR T-transplant sequencing, Dr. Park emphasizes that some patients achieve cure with CAR T-cell therapy alone, though identifying these patients prospectively remains challenging. He advocates for CAR T-cell therapy even when transplant is planned, particularly for heavily pretreated patients who received multiple prior therapies including blinatumomab, inotuzumab, and chemotherapy. Patient factors including age, prior transplant status, disease burden, and post-CAR response depth influence subsequent transplant decisions.

Dr. Muffly reinforces that CAR T-cell therapy should not be limited to non-transplant candidates, as the goal remains curing patients regardless of subsequent interventions. She acknowledges inotuzumab carries approximately 3-5% life-threatening VOD risk but emphasizes that patients cannot proceed to transplant without achieving remission, necessitating risk-benefit balancing in clinical decision-making.